← All themes

Genomics & Gene Editing

Genomics reads the genetic code and gene editing rewrites it, which can turn an inherited disease from a lifelong condition into a single treatment. Sequencing cost has fallen far enough to make study at population scale routine.

199 stocks

Gene Therapy

#	Name	Funds holding	Growth	Growth %	Fund value
151	MSGR 151 DELISTED Direxion mRNA ETF MSGR	–	–	–	–
152	152 MaxCyte MXCT $134M	–	–	–	–
153	153 NewcelX Ltd NCEL $16.5M	–	–	–	–
154	154 DELISTED NKGen Biotech, Inc. Common Stock NKGN	–	–	–	–
155	155 Nkarta NKTX $138M	–	–	–	–
156	156 Intellia Therapeutics NTLA $1.59B	–	–	–	–
157	157 OmniAb OABI $688M	–	–	–	–
158	OBX 158 Obsidian Therapeutics OBX $755M	–	–	–	–
159	159 DELISTED Omega Therapeutics, Inc. Common Stock OMGA	–	–	–	–
160	160 DELISTED Singular Genomics Systems, Inc. Common Stock OMIC	–	–	–	–
161	161 DELISTED Orgenesis Inc. Common Stock ORGS	–	–	–	–
162	ORTX 162 DELISTED Orchard Therapeutics plc American Depositary Shares ORTX	–	–	–	–
163	163 Passage Bio PASG $11.6M	–	–	–	–
164	164 PepGen PEPG $175M	–	–	–	–
165	165 PharmaCyte Biotech PMCB $3.84M	–	–	–	–
166	166 Prime Medicine PRME $655M	–	–	–	–
167	167 ProKidney PROK $305M	–	–	–	–
168	168 Personalis PSNL $1.7B	–	–	–	–
169	169 DELISTED Poseida Therapeutics, Inc. Common Stock PSTX	–	–	–	–
170	170 Quantum-Si Incorporated QSI $287M	–	–	–	–
171	RCOR 171 DELISTED Renovacor, Inc. RCOR	–	–	–	–
172	172 Atrium Therapeutics RNA $134M	–	–	–	–
173	173 Cartesian Therapeutics RNAC $199M	–	–	–	–
174	RUBY 174 DELISTED Rubius Therapeutics, Inc RUBY	–	–	–	–
175	175 Sana Biotechnology SANA $742M	–	–	–	–